A Part of the University of Maryland Medical Center

Connect with UMGCC
Facebook Twitter YouTube Blog iPhone
Email PageEmail page Print PagePrint page

UMGCC Faculty Presentations at American Society of Clinical Oncology (ASCO)

Annual Meeting May 31-June 4, 2013
Chicago, Illinois

Cancer experts at the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) presented the following research findings at the 2013 ASCO meeting:

  1. Antiemetic efficacy of transcutaneous electrical nerve stimulation (TENS) at pericardium 6 acupuncture point (P6) in the treatment of chemotherapy-induced delayed nausea and vomiting (CINV) in stage I to III breast cancer patients during adjuvant/neoadjuvant chemotherapy (Ad/nAd).
    Author(s): Jean Yared, Melody Hu, Ting Bao, Saranya Chumsri, Emily Catherine Bellavance, Susan Kesmodel, Steven J. Feigenberg, Nancy Tait, Katherine Hanna Tkaczuk; Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD; University of Maryland, Department of Anesthesiology, Pain Management Division, Baltimore, MD; Department of Medicine, University of Maryland School of Medicine

  2. Survival benefit associated with the number of chemotherapy/biologic treatment lines in 5,129 elderly metastatic colon cancer patients.
    Author(s): Nader Hanna, Zhiyuan Zheng, Corinne Woods, Ebere Onukwugha, Kaloyan A. Bikov, Brian S. Seal, C. Daniel Mullins; University of Maryland, Department of Surgery, Division of General and Oncologic Surgery, Baltimore, MD; University of Maryland, Department of Pharmaceutical Health Services Research, Baltimore, MD; University of Maryland Baltimore School of Pharmacy, Pharmaceutical Health Services Research Department, Baltimore, MD; University of Maryland School of Pharmacy, Baltimore, MD; School of Pharmacy, University of Maryland, Baltimore, MD; Bayer HealthCare Pharmaceuticals, Wayne, NJ

  3. Incremental cost (IC) analysis of skeletal related events (SREs) among elderly men with stage IV metastatic (M1) prostate cancer (PCa).
    Author(s): Jinani Jayasekera, Ebere Onukwugha, Kaloyan A. Bikov, C. Daniel Mullins, Brian S. Seal, Arif Hussain; School of Pharmacy, University of Maryland, Baltimore, MD; University of Maryland School of Pharmacy, Baltimore, MD; Bayer HealthCare Pharmaceuticals, Wayne, NJ; University of Maryland School of Medicine, Baltimore, MD

  4. Use of biologics in addition to chemotherapy in the treatment of elderly Medicare patients with stage IV metastatic colon cancer.
    Author(s): C. Daniel Mullins, Fenghao Wang, Kaloyan A. Bikov, Brian S. Seal, Nader Hanna; University of Maryland School of Pharmacy, Baltimore, MD; School of Pharmacy, University of Maryland, Baltimore, MD; Bayer HealthCare Pharmaceuticals, Wayne, NJ; University of Maryland, Department of Surgery, Division of General and Oncologic Surgery, Baltimore, MD

  5. Phase I and pharmacokinetic trial of the antitemolerase agent KML001 (KML) and cisplatin (CDDP) in advanced solid tumors.
    Author(s): Martin J. Edelman, Josephine Louella Feliciano, Miroslav Styblo, Tao Liu, Rena G. Lapidus, Jesse Saunders, Joga Gobburu; University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD; The University of North Carolina at Chapel Hill, Chapel Hill, NC; University of Maryland School of Pharmacy, Baltimore, MD; University of North Carolina, Durham, NC

  6. Levels of circulating natural killer T and natural killer cells in breast cancer patients.
    Author(s): Mya Sanda Thein, Saranya Chumsri, James Eeast, Junxin Li, Susan Kesmodel, Ting Bao, Steven J. Feigenberg, Katherine Hanna Tkaczuk, Tonya Webb; Johns Hopkins University School of Medicine, Baltimore, MD; University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD; University of Maryland, School of Medicine, Baltimore, MD

  7. Skeletal-related events (SREs), baseline comorbidity, and survival among elderly patients (pts) with metastatic (M1) prostate cancer (PCa) in SEER-Medicare.
    Author(s): Ebere Onukwugha, Candice Yong, C. Daniel Mullins, Brian S. Seal, Arif Hussain; University of Maryland School of Pharmacy, Baltimore, MD; Bayer HealthCare Pharmaceuticals, Wayne, NJ; University of Maryland School of Medicine, Baltimore, MD

  8. A pilot study of sirolimus (S) in subjects with Cowden syndrome (CS) with germ-line mutations in PTEN.
    Author(s): Takefumi Komiya, Gideon Michael Blumenthal, Marc S. Ballas, Roopa Dechowdhury, Michell Manu, Suzanne Fioravanti, Thomas J Hornyak, Stephen Wank, Douglas Weinstein, Jennifer Morris, Stephen M. Hewitt, Regan Memmott, Phillip A. Dennis, Betsy Morrow; National Cancer Institute, Bethesda, MD; U.S. Food and Drug Administration, Silver Spring, MD; Bristol-Myers Squibb, Wallingford, CT; Maryland Oncology Hematology, Silver Spring, MD; Dermatology, University of Maryland School of Medicine, Baltimore, MD; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; Laboraory of Pathology, National Cancer Institute, Gaithersburg, MD; Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD; Johns Hopkins University, Baltimore, MD; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

  9. Effect of availability of oral iron chelation therapy (ICT) on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes (MDS) and transfusional iron overload (TIO).
    Author(s): Steven Gore, Amy J. Davidoff, Franklin Hendrick, Vu Duong, Bruce C. Stuart, Maria R. Baer, Rahul Shenolikar, Amer Zeidan; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Agency for Healthcare Research and Quality, Rockville, MD; University of Maryland School of Pharmacy, Baltimore, MD; University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD; GlaxoSmithKline, Research Triangle Park, NC

  10. Frequency of rare cytogenetic abnormalities at relapse in acute myeloid leukemia (AML) with FLT3 internal tandem duplication (ITD) and normal karyotype at diagnosis: Evidence for genomic instability?
    Author(s): Theodore Stewart Gourdin, Yi Ning, Feyruz Rassool, Michael Tidwell, Vu Duong, Ashkan Emadi, Maria R. Baer; University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD

  11. Safety and efficacy of 90y resin microspheres in elderly (?70 years) compared to younger patients with colorectal liver metastases (mCRC).
    Author(s): Andrew S. Kennedy, David Ball, Steven J. Cohen, Michael Cohn, Douglas M. Coldwell, Alain Drooz, Edward Ehrenwald, Samir Kanani, Fred M Moeslein, Charles W. Nutting, Samuel G. Putnam, Steven C. Rose, Michael Savin, Sabine Schirm, Navesh K Sharma, Eric Wang; Sarah Cannon Research Institute, Nashville, TN; Fox Chase Cancer Center, Philadelphia, PA; Radiology Associates of Hollywood, Pembroke Pines, FL; James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Fairfax Radiological Consultants, Fairfax, VA; Abbott Northwestern Hospital, Minneapolis, MN; Inova Fairfax Hospital, Annandale, VA; University of Maryland Medical Center, Baltimore, MD; Radiology Imaging Associates, Englewood, CO; UC San Diego Moores Cancer Center, La Jolla, CA; Beaumont Hospital, Royal Oak, MI; Cancer Centers of North Carolina, Cary, NC; University of Maryland School of Medicine, Baltimore, MD; Charlotte Radiology, Charlotte, NC

  12. Dose reduction (DR) due to chemotherapy induced peripheral neuropathy (CIPN) in breast cancer (BC) patients (pts) in the neoadjuvant/adjuvant settings.
    Author(s): Bhavana Bhatnagar, Steven Gilmore, Olga G. Goloubeva, Lulu Wang, Michelle Medeiros, Saranya Chumsri, Katherine Hanna Tkaczuk, Martin J. Edelman, Ting Bao; University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD

  13. Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825. | 2013 ASCO Annual Meeting Abstracts
    Author(s): Terri S. Armstrong, Minhee Won, Jeffrey Scott Wefel, Mark R. Gilbert, Stephanie L. Pugh, David Brachman, Ritsuko Komaki, Ian R. Crocker, H. Ian Robins, R. Jeffrey Lee, Minesh P. Mehta, Merideth M Wendland; University of Texas Health Science Center School of Nursing, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX; Arizona Oncology Services Foundation, Phoenix, AZ; Department of Radiation Oncology, Emory University, Atlanta, GA; University of Wisconsin Hospitals and Clinics, Madison, WI; Intermtn Medcl Ctr, Salt Lake City, UT; University of Maryland, Baltimore, MD; Willamette Valley Cancer Institute, Eugene, OR

  14. Differences in sexual practices and their role in gender, age, and racial disparities in HPV-positive HNSCC.
    Author(s): Carole Fakhry, Kevin J. Cullen, Janice Bowie, Roland Thorpe, Gypsyamber D'Souza; Johns Hopkins University, Baltimore, MD; University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD; Johns Hopkins Bloomberg School of Public Health, baltimore, MD; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

  15. A phase II study of dasatanib (BMS 354825) in recurrent or metastatic ckit-expressing adenoid cystic (ACC) and non-ACC malignant salivary glands tumors (MSGT).
    Author(s): Stuart J. Wong, Ezra E.W. Cohen, Theodore Karrison, David N. Hayes, Merrill S. Kies, Kevin J. Cullen, Tawee Tanvetyanon, Athanassios Argiris, Naoko Takebe, Dean Lim, Nabil F. Saba, Francis P. Worden, Jill Gilbert, Heinz-Josef Lenz, Albiruni R.A. Razak, John D. Roberts, Everett E. Vokes; Medical College of Wisconsin, Milwaukee, WI; The University of Chicago Medicine and Biological Sciences, Chicago, IL; The University of Chicago Medical Center, Chicago, IL; Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Texas Health Science Center at San Antonio, San Antonio, TX; Investigational Drug Branch, Cancer Therapy Evaluation Program, Rockville, MD; City of Hope, Duarte, CA; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Vanderbilt University, Nashville, TN; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Princess Margaret Hospital, Toronto, ON, Canada; Massey Cancer Center, Richmond, VA

  16. Prognostic factors and outcome of atypical and anaplastic meningioma with and without radiation.
    Author(s): Hannah Yoon, Irene B. Helenowski, Karthikeyan Perumal, MaryAnne H. Marymont, James Chandler, Bernard R. Bendok, Joshua M. Rosenow, Minesh P. Mehta; Northwestern Memor Hosp - McGaw Medical Center, Chicago, IL; Northwestern University Department of Preventive Medicine, Chicago, IL; University of Wisconsin, Department of Neurological Surgery, Madison, WI; Northwestern Memorial Hospital, Chicago, IL; Northwestern University, Chicago, IL; University of Maryland, Baltimore, MD

  17. RTOG 0913: A phase I study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
    Author(s): Prakash Chinnaiyan, Minhee Won, Patrick Y. Wen, Amyn Rojiani, Merideth M Wendland, Thomas A. DiPetrillo, Benjamin W. Corn, Minesh P. Mehta; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Radiation Therapy Oncology Group, Philadelphia, PA; Dana-Farber Cancer Institute, Boston, MA; Georgia Health Sciences University, Augusta, GA; Willamette Valley Cancer Institute, Eugene, OR; Department of Radiation Oncology, Rhode Island Hospital, Providence, RI; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Maryland, Baltimore, MD

  18. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).
    Author(s): Mark R. Gilbert, James Dignam, Minhee Won, Deborah T. Blumenthal, Michael A. Vogelbaum, Kenneth D. Aldape, Howard Colman, Arnab Chakravarti, Robert Jeraj, Terri S. Armstrong, Jeffrey Scott Wefel, Paul D. Brown, Kurt A. Jaeckle, David Schiff, James Norman Atkins, David Brachman, Maria Werner-Wasik, Ritsuko Komaki, Erik P. Sulman, Minesh P. Mehta; University of Texas MD Anderson Cancer Center Department of Neuro-Oncology, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Cleveland Clinic Foundation, Cleveland, OH; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Utah, Huntsman Cancer Institute, Salt Lake City, UT; Arthur G. James Cancer Center, The Ohio State University, Columbus, OH; Department of Medical Physics, University of Wisconsin, Madison, WI; University of Texas Health Science Center School of Nursing, Houston, TX; Mayo Clinic, Jacksonville, FL; University of Virginia Medical Center, Charlottesville, VA; National Surgical Adjuvant Breast and Bowel Project and SCCC-CCOP, Goldboro, NC; Arizona Oncology Services Foundation, Phoenix, AZ; Thomas Jefferson University Hospital, Philadelphia, PA; University of Maryland, Baltimore, MD

  19. Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance.
    Author(s): Kenneth H. Yu, Vineet Sangar, Mark Ricigliano, Manuel Hidalgo, Ghassan K. Abou-Alfa, Maeve Aine Lowery, Leonard Saltz, Joseph F. Crotty, Kristen Gary, Jing Yin, Eun Yong Choi, Eileen Mary O'Reilly; Memorial Sloan-Kettering Cancer Center, New York, NY; Institute for Systems Biology, Seattle, WA; CellPath Therapeuthics, Inc, Baltimore, MD; Spanish National Cancer Research Center (CNIO), Madrid, Spain; University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD

  20. Preirradiation chemotherapy with methotrexate, rituximab, and temozolomide and post-irradiation temozolomide for primary central nervous system lymphoma: RTOG 0227 phase II study results.
    Author(s): Jon Glass, Minhee Won, Christopher J. Schultz, Daniel Brat, Nancy Bartlett, John H. Suh, Barbara Jean Fisher, Marcia K. Liepman, Minesh P. Mehta; Thomas Jefferson University, Philadelphia, PA; Radiation Therapy Oncology Group, Philadelphia, PA; Medical College of Wisconsin, Milwaukee, WI; Emory University, Atlanta, GA; Washington University School of Medicine in St. Louis; Siteman Cancer Center, St. Louis, MO; Cleveland Clinic, Cleveland, OH; Department of Radiation Oncology, London Regional Cancer Program, London, ON, Canada; West Michigan Cancer Center, Kalamazoo, MI; University of Maryland, Baltimore, MD

  21. HIV-associated high-risk HPV infection in Nigerian women.
    Author(s): Sally Nneoma Akarolo-Anthony, Celestine C. Ogbonna, Oluranti Ayotunde Famooto, Eileen O. Dareng, Maryam Al-Mujtaba, George Odonye, Olayinka Olaniyan, Richard Offiong, Ishak Lawal, Cosette Wheeler, Clement Adebayo Adebamowo; Harvard School of Public Health, Boston, MA; Institute of Human Virology, Abuja, Nigeria; National Hospital, Abuja, Nigeria; University of Abuja Teaching Hospital, Abuja, Nigeria; University of New Mexico, Albuquerque, NM; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD
  22. Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).
    Author(s): Sally Nneoma Akarolo-Anthony, Celestine C. Ogbonna, Oluranti Ayotunde Famooto, Eileen O. Dareng, Maryam Al-Mujtaba, George Odonye, Olayinka Olaniyan, Richard Offiong, Ishak Lawal, Cosette Wheeler, Clement Adebayo Adebamowo; Harvard School of Public Health, Boston, MA; Institute of Human Virology, Abuja, Nigeria; National Hospital, Abuja, Nigeria; University of Abuja Teaching Hospital, Abuja, Nigeria; University of New Mexico, Albuquerque, NM; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD

  23. Understanding the experience of living with non-small cell lung cancer (NSCLC): A qualitative study.
    Author(s): Joanne S. Buzaglo, Christopher Gayer, Rajiv Mallick, Ellyn Micco, Anne Morris, Andrea Stern Ferris, Mitch Golant, Corey J. Langer, C. Daniel Mullins, David Cella; Cancer Support Comunity, Research and Training Institute, Philadelphia, PA; Daiichi Sankyo Co., Ltd., Parsippany, NJ; Fox Chase Cancer Center, Philadelphia, PA; Lungevity, Alexandria, VA; Cancer Support Comunity, Research and Training Institute, Los Angeles, CA; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; University of Maryland School of Pharmacy, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

  24. Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.
    Author(s): Daniel Virgil Thomas Catenacci, Nathan Bahary, Sreenivasa R. Nattam, Robert de Wilton Marsh, James Alfred Wallace, Lakshmi Rajdev, Deirdre Jill Cohen, Bethany G. Sleckman, Heinz-Josef Lenz, Patrick J. Stiff, Sachdev P. Thomas, Peng Xu, Les Henderson, Margit Naomi Horiba, Michael Vannier, Theodore Karrison, Walter Michael Stadler, Hedy Lee Kindler; University of Chicago, Chicago, IL; University of Pittsburgh Medical Center, Pittsburgh, PA; Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN; Kellogg Cancer Center NorthShore University Health System, Evanston, IL; Ingalls Memorial Hospital/Cancer Research Center, Harvey, IL; Montefiore Medical Center, Bronx, NY; New York University Cancer Institute, New York, NY; St. John's Mercy Medical Center, St. Louis, MO; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Loyola University Medical Center, Maywood, IL; Illinois Cancer Care, Peoria, IL; University of Maryland, Baltimore, MD; The University of Chicago Medical Center, Chicago, IL; The University of Chicago, Chicago, IL
  25. RTOG 0618: Stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients.
    Author(s): Robert D. Timmerman, Rebecca Paulus, Harvey I. Pass, Elizabeth Gore, Martin J. Edelman, James M. Galvin, Hak Choy, William Straube, Lucien Alexander Nedzi, Ronald McGarry, Cliff Grant Robinson, Peter B. Schiff, Jeffrey D. Bradley; The University of Texas Southwestern Medical Center, Dallas, TX; Radiation Therapy Oncology Group, Statistical Center, Philadelphia, PA; New York University School of Medicine, New York, NY; Medical College of Wisconsin, Milwaukee, WI; University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD; Thomas Jefferson University Hospital, Philadelphia, PA; Washington University in St. Louis, St. Louis, MO; University of Kentucky, Lexington, KY

  26. Discriminatory power of a 25-item distress screening tool CancerSupport Source: A cross-sectional study of 251 cancer survivors.
    Author(s): Melissa F Miller, C. Daniel Mullins, Ebere Onukwugha, Christopher Gayer, Mitch Golant, Joanne S. Buzaglo; Cancer Support Comunity, Research and Training Institute, Philadelphia, PA; University of Maryland School of Pharmacy, Baltimore, MD; Cancer Support Comunity, Research and Training Institute, Los Angeles, CA

  27. A randomized, open-label phase II study of single-agent vintafolide versus vintafolide plus docetaxel versus docetaxel alone in second-line NSCLC patients with all target lesions expressing folate-receptor (TARGET).
    Author(s): Martin J. Edelman, Hong Ma, Wendy Perez, Alex A. Adjei, Nader Hanna; University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD; Endocyte, Inc., West Lafayette, IN; Roswell Park Cancer Institute, Buffalo, NY; Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN

  28. Randomized phase II trial of gemcitabine versus gemcitabine and imatinib mesylate in patients with previously treated metastatic breast cancer.
    Author(s): Pashna Neville Munshi, Deborah Toppmeyer, Serena Tsan-Lai Wong, Shridar Ganesan, Katherine Hanna Tkaczuk, Mary E. Cianfrocca, Virginia G. Kaklamani, William John Gradishar, Robert A. Somer, Kanu Sharan, Generosa Grana, Pauline Marie O. Lerma, Lillian F. Pliner, Robert Wieder, Michael P. Kane, Sinae Kim, Antoinette R. Tan; University of Medicine and Dentistry of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, NJ; The Cancer Institute of New Jersey, New Brunswick, NJ; University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD; Banner MD Anderson Cancer Center, Gilbert, AZ; Northwestern University, Chicago, IL; Cooper University Hospital, Camden, NJ; UMDNJ-New Jersey Medical School, Newark, NJ

  29. An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC).
    Author(s): Tom Stinchcombe, Lynette M. Sholl, Xiaofei F. Wang, Lin Gu, Mark A. Socinski, Scott J. Rodig, Marzia Capelletti, Jeffrey Crawford, Martin J. Edelman, Miguel Angel Villalona-Calero, Robert Arthur Kratzke, Everett E. Vokes, Vincent A. Miller, Pasi Antero Janne, Alliance; The University of North Carolina at Chapel Hill, Chapel Hill, NC; Dana-Farber Cancer Institute/Brigham and Women?s Hospital, Boston, MA; Cancer and Leukemia Group B Statistical Center, Durham, NC; University of Pittsburgh Medical Center, UPMC Cancer Pavilion, Pittsburgh, PA; Department of Pathology, Division of Hematopathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Duke University Medical Center, Durham, NC; University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD; The Ohio State University Wexner Medical Center, Columbus, OH; University of Minnesota, Minneapolis, MN; The University of Chicago Medicine and Biological Sciences, Chicago, IL; Foundation Medicine, Inc., Cambridge, MA

This page was last updated on: May 29, 2013.